๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Xuzhou
Clinical trial register · China

Clinical Trials in Xuzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Xuzhou 24 Fuyang 1 Huai'an 1 Lianyungang 1 Nanjing 1
Narrow the registerReset
Recruitment status
Phase
Site location
Xuzhou24 Fuyang1 Huai'an1 Lianyungang1 Nanjing1
All 8 locations
Target enrolment
to

Trials with a site in Xuzhou

24 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)
NCT07413835Refractory Myasthenia Gravis
The Affiliated Hospital of Xuzhou Medical University
Not applicable
6
Xuzhou
2026-03-17
Recruiting
Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
NCT07680933DLBCL - Diffuse Large B Cell Lymphoma
The Affiliated Hospital of Xuzhou Medical University
Phase 2
30
Xuzhou
2026-03-01
Not yet open
Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients
NCT06683131Acute Myocardial Infarction (AMI)
The Affiliated Hospital of Xuzhou Medical University
Phase 4
1,160
Fuyang, Huai'an, Lianyungang, Nanjing, Suqian, Xuzhou, Beijing, Shanghai
2025-11-20
Recruiting
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
NCT07285395Advanced Solid Tumors
The Affiliated Hospital of Xuzhou Medical University
Phase 1
12
Xuzhou
2025-11-12
Recruiting
Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL
NCT07120633CLL, CAR-T Cell Therapy, SLL
The Affiliated Hospital of Xuzhou Medical University
Not applicable
50
Xuzhou
2025-09-01
Recruiting
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL
NCT07168317New Diagnosed Angioimmunoblastic T-Cell Lymphoma
The Affiliated Hospital of Xuzhou Medical University
Phase 2
40
Xuzhou
2025-08-01
Not yet open
High-Frequency QRS for Predicting Microvascular Dysfunction and Adverse Events After PCI in Acute Myocardial Infarction
NCT07138638AMI
The Affiliated Hospital of Xuzhou Medical University
Observational
1,112
Xuzhou
2025-08
Not yet open
Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
NCT07034755Multiple Myeloma (MM), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Chimeric Antigen Receptor T-cell
The Affiliated Hospital of Xuzhou Medical University
Not applicable
20
Xuzhou
2025-07-01
Not yet open
A Prospective Study on IVUS and DSA Guidance in the Treatment of Budd-Chiari Syndrome
NCT06960473Budd-Chiari Syndrome
The Affiliated Hospital of Xuzhou Medical University
Not applicable
260
Xuzhou
2025-05-18
Recruiting
Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL
NCT07058103Angioimmunoblastic T-Cell Lymphoma Recurrent, Angioimmunoblastic T-Cell Lymphoma Refractory
The Affiliated Hospital of Xuzhou Medical University
Phase 2
40
Xuzhou
2025-04-01
Active, closed
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT07155369Systemic Lupus Erythematosus, Systemic Sclerosis
The Affiliated Hospital of Xuzhou Medical University
Not applicable
18
Xuzhou
2025-03-18
Active, closed
To Evaluate the Effect and Safety of Telitacicept and Standard Treatment for 6months in IgA Nephropathy
NCT07098897IgA Nephropathy (IgAN)
The Affiliated Hospital of Xuzhou Medical University
Phase 3
150
Xuzhou
2024-08-01
Recruiting
Predictive Role of sTREM in Endovascular Thrombectomy Outcomes
NCT06545591Acute Ischemic Stroke
The Affiliated Hospital of Xuzhou Medical University
Observational
300
Xuzhou
2024-07-01
Recruiting
Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective Study
NCT06614998Hemophagocytic Syndrome
The Affiliated Hospital of Xuzhou Medical University
Observational
80
Xuzhou
2024-05-01
Recruiting
Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM
NCT06256419Type 2 Diabetes Mellitus, Susceptibility, Genetic
The Affiliated Hospital of Xuzhou Medical University
Not applicable
300
Xuzhou
2024-01-01
Recruiting
Effect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and Controls
NCT06277466Type 2 Diabetes Mellitus, Gene Polymorphisms, Genetic Mutations, Susceptibility, Genetic
The Affiliated Hospital of Xuzhou Medical University
Not applicable
300
Xuzhou
2024-01-01
Recruiting
BGT007H Cells for the Treatment of Refractory Digestive System Tumors
NCT06104215Digestive Tract Cancer
The Affiliated Hospital of Xuzhou Medical University
Phase EARLY_PHASE1
14
Xuzhou
2023-10-22
Recruiting
BGT007 Cells for the Treatment of Refractory Digestive System Tumors
NCT06104241Gastrointestinal Cancer
The Affiliated Hospital of Xuzhou Medical University
Phase EARLY_PHASE1
14
Xuzhou
2023-10-22
Active, closed
Heart Failure With Preserved Ejection Fraction and Its Cardiac MR Characteristics of Different Subtypes
NCT06916611HFpEF, Heart Failure With Preserved Ejection Fraction
The Affiliated Hospital of Xuzhou Medical University
Observational
500
Xuzhou
2023-05-01
Recruiting
Surgical-imaging Research on Obesity (SIRO)
NCT06268262Overweight and Obesity
The Affiliated Hospital of Xuzhou Medical University
Observational
200
Xuzhou
2023-03-01
Recruiting
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
NCT05354375Immunotherapy
The Affiliated Hospital of Xuzhou Medical University
Phase 1
20
Xuzhou
2022-12-01
Recruiting
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
NCT05323201Hepatocellular Carcinoma
The Affiliated Hospital of Xuzhou Medical University
Phase 1/2
15
Xuzhou
2022-02-10
Recruiting
Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma
NCT04969354Immunotherapy
The Affiliated Hospital of Xuzhou Medical University
Phase 1
20
Xuzhou
2021-10-01
Active, closed
Early CMR in Acute MI
NCT07602439Acute Myocardial Infarction (AMI)
The Affiliated Hospital of Xuzhou Medical University
Observational
2,000
Xuzhou
2018-10-31
Rows per page Showing 1–24 of 24
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/xuzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 24 of those studies with a site in Xuzhou that also match the filters currently applied.

How many clinical trials are recruiting in Xuzhou?

16 of the 24 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Xuzhou), 24 studies
PhaseStudiesRecruitingShare
Not applicable7429.2%
Observational6325%
Phase 13312.5%
Phase 23312.5%
Phase EARLY_PHASE1228.3%
Phase 1/2114.2%
Phase 3104.2%
Phase 4104.2%

Most active sponsors

Lead sponsors with the most studies (Xuzhou)
Lead sponsorStudiesRecruiting
The Affiliated Hospital of Xuzhou Medical University2416
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.